MohammadJahanzebMD

PubMed

• 1 citations
  Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States.
  Mohammad Jahanzeb, Huamao M Lin, Yanyu Wu, Pingkuan Zhang, Magdaliz Gorritz, Catherine B McGuiness, Wei-Ti Huang, Kainan Sun, Chi-Chang Chen, D Ross Camidge> ;The Oncologist. 2022 Sep 2
• 5 citations
  Multi-omic molecular profiling guide's efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial.
  Mariaelena Pierobon, Nicholas J. Robert, Donald W. Northfelt, Mohammad Jahanzeb, Shukmei Wong, Kimberly A. Hodge, Elisa Baldelli, Jessica Aldrich, David Craig, Lance A...> ;Molecular Oncology. 2021 Sep 12
• 9 citations
  Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK + non-small cell lung cancer (ALTA-1L)
  Maria Rosario Garcia Campelo, Huamao M. Lin, Yanyan Zhu, Maurice Pérol, Mohammad Jahanzeb, Sanjay Popat, Pingkuan Zhang, D. Ross Camidge> ;Lung Cancer. 2021 Mar 9
• 5 citations
  Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry
  Peter A. Kaufman, Sara A. Hurvitz, Joyce O'Shaughnessy, Ginny Mason, Denise A. Yardley, Adam Brufsky, Hope S. Rugo, Melody A. Cobleigh, Sandra M. Swain, Debu Tripathy,...> ;Breast Cancer Research and Treatment. 2021 Feb 28
• Treatment of anaplastic lymphoma kinase-positive lung adenocarcinoma with pemetrexed and carboplatin after crizotinib failure and significant liver dysfunction; a case...
  Oranus Mohammadi, Kayla Haines, Mohammad Jahanzeb> ;Cancer Treatment and Research Communications. 2021 Jan 1
• 36 citations
  Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non–Small-Cell Lung Cancer
  Mohammad Jahanzeb, Huamao M. Lin, X. Pan, Y. Yin, Pia Baumann, Corey J. Langer> ;Clinical Lung Cancer. 2021 Jan 1
• 62 citations
  Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial.
  James Chih-Hsin Yang, D. Ross Camidge, Cheng-Ta Yang, Jianying Zhou, Renhua Guo, Chao Hua Chiu, Gee-Chen Chang, Her Shyong Shiah, Yuan Chen, Chin Chou Wang, David Berz...> ;Journal of Thoracic Oncology. 2020 Dec 1
• 1 citations
  Remarkable Role of Chemotherapy in Selected ALK-Positive Non–Small-Cell Lung Cancer Before or After Targeted Therapy: Two Case Reports
  Kunal Gawri, Richa Dawar, Kayla Haines, Mohammad Jahanzeb> ;JCO Precision Oncology. 2020 Nov 18
• 18 citations
  Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cel...
  Mohammad Jahanzeb, Huamao M. Lin, X. Pan, Y. Yin, Yanyu Wu, Beth Nordstrom, Mark A. Socinski> ;The Oncologist. 2020 Oct 1
• 1 citations
  Response to Abemaciclib After 10 Lines of Therapy Including Palbociclib in Metastatic Breast Cancer: A Case Report With Literature Review
  Isabella Osorio Wender, Kayla Haines, Mohammad Jahanzeb> ;Oncology and Therapy. 2020 Sep 2
• 1 citations
  Improving Quality of Cancer Care by Participating in Quality Oncology Practice Initiative Certification Program.
  Abdul Rahman Jazieh, Nafisa Abdelhafiez, Nashmia Al Mutairi, Ahmed Hashem, Mohammad Alkaiyat, Mona Al Shami, Mohammad Jahanzeb> ;JCO Global Oncology. 2020 Jul 16
• 9 citations
  Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors
  Huamao M. Lin, X. Pan, Peijie Hou, Hui Huang, Yanyu Wu, Kaili Ren, Mohammad Jahanzeb> ;Journal of Medical Economics. 2020 May 21
• 1 citations
  International Perspective on the Pursuit of Quality in Cancer Care: Global Application of QOPI and QOPI Certification
  Douglas W. Blayney, Nafisa Albdelhafeez, Abdul Rahman Jazieh, Carlos Frederico Pinto, Adrian Udrea, Alex Roach, Devika Govind Das, Stephen Grubbs, John Hamm, Mohammad ...> ;JCO Global Oncology. 2020 May 6
• 5 citations
  Resource-Stratified Guideline-Based Cancer Care Should Be a Priority: Historical Context and Examples of Success.
  Natasha Hunter, Naomi Dempsey, Fayez Tbaishat, Mohammad Jahanzeb, Sana Al-Sukhun, Julie R. Gralow> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2020 Mar 31
• 15 citations
  Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs.
  Melody A. Cobleigh, Denise A. Yardley, Adam Brufsky, Hope S. Rugo, Sandra M. Swain, Peter A. Kaufman, Debu Tripathy, Sara A. Hurvitz, Joyce O'Shaughnessy, Ginny Mason,...> ;Clinical Cancer Research. 2020 Mar 1
• 25 citations
  Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer.
  Wungki Park, Laura Mezquita, Naoyuki Okabe, Young Kwang Chae, Deukwoo Kwon, Diana Saravia, Edouard Auclin, David Planchard, Caroline Caramella, Roberto Ferrara, Sarita...> ;British Journal of Cancer. 2020 Feb 4
• 21 citations
  De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
  Debu Tripathy, Adam Brufsky, Melody Cobleigh, Mohammad Jahanzeb, Peter A Kaufman, Ginny Mason, Joyce O'Shaughnessy, Hope S Rugo, Sandra M Swain, Denise A Yardley, Laur...> ;The Oncologist. 2020 Feb 1
• 49 citations
  Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs
  Sara A. Hurvitz, Joyce O'Shaughnessy, Ginny Mason, Denise A. Yardley, Mohammad Jahanzeb, Adam Brufsky, Hope S. Rugo, Sandra M. Swain, Peter A. Kaufman, Debu Tripathy, ...> ;Clinical Cancer Research. 2019 Apr 15
• 26 citations
  Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET t...
  Joanne E. Mortimer, Jack A. Di Palma, Kendra K. Schmid, Yining Ye, Mohammad Jahanzeb> ;Breast Cancer Research. 2019 Feb 27
• 16 citations
  Update on Precision Medicine in Breast Cancer.
  Jasgit C. Sachdev, Ana C. Sandoval, Mohammad Jahanzeb> ;Cancer Treatment and Research. 2019 Jan 1
• 18 citations
  Use of Patient-Reported Outcome Measures in Quality Oncology Practice Initiative–Registered Practices: Results of a National Survey
  Biqi Zhang, Whitney Lloyd, Mohammad Jahanzeb, Michael J. Hassett> ;Journal of Oncology Practice. 2018 Sep 12
• 45 citations
  Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab
  Wungki Park, Deukwoo Kwon, Diana Saravia, Amrita Desai, Fernando Vargas, Mohamed El Dinali, Jessica R. L. Warsch, Roy Elias, Young Kwang Chae, Dae Won Kim, Sean Warsch...> ;Clinical Lung Cancer. 2017 Dec 1
• Patient with typical carcinoid initially diagnosed as high-grade neuroendocrine carcinoma.
  Sean Warsch, Mohammad Jahanzeb> ;Lung Cancer Management. 2017 Oct 26
• 64 citations
  Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.
  Mariaelena Pierobon, Corinne Ramos, Shukmei Wong, K. Alex Hodge, Jessica Aldrich, Sara A. Byron, Stephen P. Anthony, Nicholas J. Robert, Donald W. Northfelt, Mohammad ...> ;Clinical Cancer Research. 2017 Aug 15
• 32 citations
  Choosing Wisely in Oncology: Are We Ready For Value-Based Care?
  Gabrielle B. Rocque, Douglas W. Blayney, Mohammad Jahanzeb, August Knape, Merry Jennifer Markham, Trang Pham, Jeremy Shelton, Preeti Sudheendra, Tracey L. Evans> ;Journal of Oncology Practice. 2017 Aug 7
• Join now to see all

Journal Articles

• “SWOG S0802: A Randomized Phase II Trial of Weekly Topotecan with and without Ziv-aflibercept in Patients with Platinum-Treated Small Cell Lung Cancer”  
  Allen J, Moon J, Redman M, Gadgeel S, Kelly K, Mack P, Saba H, Mohamed M, Jahanzeb M, and David R Gandara, Journal of Clinical Oncology/ J Clin Oncol., 1/7/2014
• “Adverse Event Management in Patients With Advanced Cancer Receiving Oral Everolimus: Focus on Breast Cancer”  
  Aapro M, Andre F, Blackwell K, Calvo E, Jahanzeb M, Papazisis K, Porta C, Pritchard K, Ravaud A, Annals of Oncology, 1/1/2014
• “Non-Small Lung Cancer: “Clinical Practice Guidelines in Oncology”  
  Ettinger DS, Akerley W, Borhhaei H, Chang AC, Cheney RT, Chirieac LR, D’Amico TA, Demmy TL, Ganti AK, Govindan, R, Grannis, Jr. FW, Horn L, Jahan TM, Jahanzeb M, Kessi..., J National Comprehensive Cancer Network, 1/1/2012
• “Malignant Pleural Mesothelioma”  
  Ettinger DS, Akerley, Jahanzeb M, et.al., JNatl Compr Canc Netw., 1/1/2012
• “Blockade of the HER family of Receptors in the Treatment of HER2-Positive Metastatic Breast Cancer” Clinical Breast Cancer, Vol 12, No 1, 19-29 ©Mahtani R, Khan R, Ja...  
  Sachdev J, Jahanzeb M, Clin Lung Cancer, 1/1/2011
• “Neoadjuvant bevacizumab with weekly nanoparticle albumin bound (nab)-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple negativ...  
  Snider JN, Allen JW, Young R, Schwartzberg L, Javed Y, Jahanzeb M, Sachdev JC, J Clin Oncol, 1/15/2010
• “Does race affect outcomes in triple negative breast cancer?"  
  Sachdev JC, Ahmed S, Mirza MM, Farooq A, Kronish L, Jahanzeb M, Breast Cancer, 1/7/2010
• “Modification and Implementation of NCCN Guidelines on Breast Cancer in the Middle East and North Africa Region”  
  Abulkhair O, Saghi L, Saadedin A, Elzahwary H, Siddiqui N, Al Saleh M, Geara F, Birido N, Al-Eissa N, Sukhun SA, Abdulkareem H, Ayoub MM, Deirawan F, Fayaz S, Kandil A..., J Natl Compr Canc Netw., 1/1/2010
• “Modification and Implementation of NCCN Guidelines on Non-Small Cell Lung Cancer in the Middle East and North Africa Region"  
  Jazieh AR, Bamefleh H, Demirkazik A, Gaafar RM, Geara FB, Javaid M, Khader J, Omar W, Saadeddin A, Sabe HA, Shadmehr MB, El Sherif A, Uddin N, Jahanzeb M, Ettinger D; ..., J Natl Compr Canc Netw., 1/1/2010
• NCCN Oncology Risk Evaluation and Mitigation Strategies (REMS) Work Group  
  Johnson PE, Dahlman G, Eng K, Garg R, Gottlieb S, Hoffman JM, Howell P, Jahanzeb M, Johnson S, Mackler E, Rubino M, Sarokhan B, Marc Stewart F, Tyler T, Vose, JM, Wein..., J Natl Compr Canc Netw., 1/1/2010
• “The Abu Dhabi Declaration: Adapted Application of NCCN Clinical Practice Guidelines in Oncology in the Middle East and North Africa Region”  
  Jazieh A, Azim H, McClure J, Jahanzeb M, Journal of the National. Comprehensive Cancer Network, 1/1/2010
• “The process of NCCN Guidelines adaptation to the Middle East and North Africa Region”  
  Jazieh AR, Azim HA, McClure J, Jahanzeb M, J Natl Compr Canc Netw., 1/1/2010
• “Modification and Implementation of NCCN Guidelines on Breast Cancer in the Middle East and North African Region"  
  Abulkhair O, Saghir N, Sedky L, Saadedin A, Elzahwary H, Saddiqui N, Al Saleh M, Geara F, Birido N, Al Eissa N, Sukhun SA, Abdulkareem H, Ayoub MM, Deirawan F, Fayaz S..., J Natl Compr Canc Netw., 1/1/2010
• “The Process of NCCN Guidelines Adaptation to the Middle East and North African Region”  
  Jazieh AR, Azim HA, McClure J, Jahanzeb M, J Natl Compr Canc Netw., 1/1/2010
• “Modification and Implementation of NCCN Guidelines on Non-Small Lung Cancer in the Middle East and North Africa Region”  
  Jazieh AR, Bamefleh H, Demirkazik A, Gaafar RM, Javaid M, Khader J, Khodadad K, Omar W, Saadeddin A, Sabe HA, Shadmehr MB, El Sherif A, Uddin N, Jahanzeb M, Ettinger D..., J National Comprehensive cancer Network, 1/1/2010
• “NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: “Recommendations for Stakeholders”  
  Johnson PE, Dahlman G, Eng K, Garg R, Gottlieb S, Hoffman J, Howell P, Jahanzeb M, et al., Journal of the National Comprehensive Cancer Network, 1/1/2010
• “The Abu Dhabi Declaration: Adapted Application of NCCN Clinical Practice Guidelines in Oncology in the Middle East and North Africa Region”  
  Jazieh A, Azim H, McClure J, Jahanzeb M, Journal of the National Comprehensive Cancer Network, 1/1/2010
• “Bisphophonates as anticancer therapy for early breast cancer”  
  Mahtani R, Jahanzeb M, Clinical Breast Cancer, 1/1/2010
• “Non-small cell lung cancer”  
  Ettinger D, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D’Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, JahanT, Jahanzeb M, et al., Journal of the National Comprehensive Cancer Network, 1/1/2010
• “Bisphosphonates in lung cancer: more than a palliative therapy?”  
  Jahanzeb M, et al., Seminars in Oncology, 1/1/2010
• “NCCN Clinical Practice Guidelines in Oncology, Non-Small Cell Lung Cancer”  
  Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney R, Chirieac LR, D’Amico TA, Demmy TL, Govindan R, Grannis FW, Jahan T, Jahanzeb M, et al., National Comprehensive Cancer Network, 1/1/2010
• “NCCN Clinical Practice Guidelines in Oncology, Breast Cancer”  
  Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, hudis CA, Jahanz..., National Comprehensive Cancer Network, 1/1/2010
• “Bisphosphonates as Anticancer Therapy for Early Breast Cancer”  
  Mahtani R, Jahanzeb M, Clinical Breast Cancer, 1/1/2010
• “Bisphosponates in lung cancer: more than a palliative therapy?”  
  Jahanzeb M, et al., Seminars in Oncology, 1/1/2010
• “Anastozole versus Exemestane in patients with postmenopausal breast cancer and visceral metastases”  
  Schreiber A, Sachdev J, Jahanzeb M, Clinical Medicine Reviews in Oncology, 1/1/2010
• Join now to see all

Books/Book Chapters

• “Lung Cancer: A Practical Guide” 
  Page 111 - 123Raez L, Silva O, Jahanzeb MElsevier Limited2008
• NCCN Lung Cancer Treatment Guidelines for Patients, Version II 
  Jahanzeb M, et.al.JNCCN2004
• The Washington Manual of Oncology 
  Chapter: "Breast Cancer" 
  Page 112 - 142Chantler ML, and Jahanzeb MLippincott Williams & Wilkins2002
• The Chemotherapy Source Book 
  Chapter: “Chemotherapy of Lung Cancer” 
  Page 1103 - 1123Jahanzeb M and Ihde DCEditors: Perry MC.Williams & Wilkins, Philadelphia, PAEdition 2nd,1995
• Join now to see all

Abstracts/Posters

• A Randomized, Phase II Trial of Weekly Topotecan With and Without Ziv-Aflibercept in Patients With Platinum-Treated Small-Cell Lung Cancer.
  J, Redman M, Gadgeel SM, Kelly K, Mack PC, Saba HM, Mohamed MK, Jahanzeb M, Gandara DR, Southwest Oncology Allen JW, Moon Group S0802, J Clin Oncol., 1/7/2014
• "The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic ...
  Tripathy D1, Rugo HS, Kaufman PA, Swain S, O'Shaughnessy J, Jahanzeb M, Mason G, Beattie M, Yoo B, Lai C, Masaquel A, Hurvitz S., 1/2/2014
• “Increasing proportion of de novo compared with recurrent HER2-positive metastatic breast cancer: early results from the Systemic Therapies for HER2-Positive Metastati...
  Tripathy D, Brufsky A, Cobleigh M, Jahanzeb M, Kaufman P, Mason G, Mayer M, O’Shaughnessy J, Rugo S. H, Swain. M S, Yardley A. D, Beattie M, Yoo B, Hurvitz S, SABCS, 1/1/2014
• Effectiveness and safety of post-induction phase bevacizumab treatment for patients with non small-cell lung cancer: results from the ARIES observational cohort study.
  MP Kosty,1 A Wozniak,2 M Jahanzeb,3 L Leon,4 S. Fish,4 S. Hazard,4 TJ Lynch Jr5, 1/1/2014
• “Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer.”
  Aapro M1, Andre F, Blackwell K, Calvo E, Jahanzeb M, Papazisis K, Porta C, Pritchard K, Ravaud A, Ann Oncol., 1/1/2014
• Pathway activation mapping metastatic breast cancer identifies potential organ-specific signatures: implications for patient stratification to targeted treatment.
  Pierobon M, Anthony SP, Reeder A, Nicholas Robert, D. Northfelt, M. Jahanzeb, Vocila L, Wulfkuhle J, Dunetz B, Liotta L, Petricoin E. F., San Antonio Breast Cancer Symposium, 1/1/2014
• Clinical impact of internet-based tools to help guide therapeutic decisions for metastatic breast cancer (MBC).
  KL Obholz, KL Blackwell, S Glück, M Jahanzeb, KD Miller, NJ Robert, AD Bowser, J Mortimer, and RW Carlson, Cancer Research, 1/15/2013
• “Phase 2 Double-Blind, Placebo-Controlled Doublet in Subjects with Previously Untreated Folate Receptor Alpa (FRA) Expressing Non Small Cell Lung Cancer (NSCLC)”.
  Maltzman JD, Fatato P, Hoffman K, Dougherty K, O’Shannessy D, Somers EB, Cobo M, Felip E, Jahanzeb M; Morphotek, Exton, PA; Hospital Regional Universitario Carlos Hay..., Poster Presentation, IASLC, 1/1/2013
• “High pathologic complete response (pCR) with weekly nanoparticle albumin bound (nab-P) + carboplatin (C) followed by doxorubicin plus cyclophoshamide (AC) with concu...
  Snider JN, Sachdev JC, Allen JW, Schwartzberg LS, Young RR, Javed AY, Yunus F, Verrier CS, Jahanzeb M; University of Tennessee, Memphis, TN; Virginia G. Piper Cancer C..., Proceedings of ASCO, 1/1/2013
• “Neoadjuvant bevacizumab with weekly nanoparticle albumin bound (nab)-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple negativ...
  Sachdev JC, Kronish LE, West S, Schwartzberg L, Jahanzeb M, ASCO 2010, 1/15/2012
• "Neoadjuvant Bevacizumab with Weekly Nanoparticle Albumin Bound (nab)-Paclitaxel Plus Carboplatin Followed by Doxorubicin Plus Cyclophosphamide (AC) for Triple Negativ...
  Snider JN, Allen JW, Young R, Schwartzberg L, Javed Y, Jahanzeb M, Sachdev JC, SABCS, 1/1/2012
• “Non-small cell lung cancer.”
  Ettinger D, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D’Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, JahanT, Jahanzeb M, et al., J Natl Comp Canc Netw., 1/1/2012
• Neoadjuvant bevacizumab with weekly nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer.
  Snider, J Young,R Schwartzberg, L….. Jahanzeb, M and Sachdev J, PASCO, 1/1/2012
• “Cumulative Exposure to Bevacizumab (BV) After Induction Therapy (tx) Correlates with Increased Survival in Patients (pts) with Non-small Cell Lung Cancer (NSCLC)”
  Wozniak A, Jahanzeb M, Lynch T, Stockholm Congress/ECCO/ESMO Poster Presentation, 1/1/2011
• “Use of Bevacizumab (BV) After Induction Therapy is Associated with Survival Benefit in Patients (pts) with Non-small Cell Lung Cancer (NSCLC) in the ARIES Observation...
  Brahmer J, Jahanzeb M, Priya K, Robles R, Wozniak A, Lynch T, Stockholm Congress/ECCO/ESMO Poster Presentation, 1/1/2011
• “Clinical Outcomes for Bevacizumab (BV)-treated Elderly Patients with Non-small Cell Lung Cancer (NSCLC): Results from the ARIES Observational Cohort Study (OCS)”
  Kosty M, Jahanzeb M, Garst J, Spigel D, Leon L, Wendlberger S, Schnurr J, Photowala H, Stockholm Congress/ECCO/ESMO Poster Presentation, 1/1/2011
• Reducing the Risk for Breast Cancer Recurrence After Completion of TamoxifenTreatment in Postmenopausal Women.
  Jahanzeb M, Clinical Therapeutics, 1/1/2007
• A multicenter phase II trial of carboplatin, vinorelbine, and trastuzumab in previously untreated patients with HER2 positive metastatic breast cancer.
  Sachdev J, Jahanzeb M, SABCS, 1/1/2007
• Empiric dose reduction of pegfilgrastin in breast cancer patients receiving cytotoxic chemotherapy.
  Waheed S, Jahanzeb M, SABCS, 1/1/2007
• Dose dense neoadjuvant treatment of women with breast cancer utilizing docetaxel, vinorelbine and trastuzumab with growth factor support.
  Jahanzeb M, Limentani SA, et.al, Selected for poster presentation at American Society of Clinical Oncology Annual Meeting, 1/1/2005
• A practice-based, voluntary program for promoting excellence in cancer care: A Pilot study of feasibility, cost and preliminary results.
  Desch CE, Eisenberg D, Gesme D, Jacobson J, Jahanzeb M, et.al., American Society of Clinical Oncology Annual Meeting, 1/1/2004
• “Advances with Trastuzumab/Chemotherapy in Metastatic Breast Cancer: Tidbits from Texas (the 2002 San Antonio Breast Cancer Symposium)”
  Jahanzeb M, Cancer Abstracts and Summaries, 1/1/2003
• Dose dense neoadjuvant treatment of women with breast cancer utilizing docetaxel and vinorelbine with growth factor supplements.
  Limentani SA, Brufsky AM, Erban JK, Jahanzeb M, Lewis D, San Antonio Breast Cancer Symposium, 1/1/2003
• Dose dense neoadjuvant treatment of women with breast cancer utilizing docetaxel, vinorelbine and trasturzumab with growth factor support.
  Limentani SA, Brufsky AM, Erban JK, Jahanzeb M, Lewis D, San Antonio Breast Cancer Symposium, 1/1/2003
• Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide for stage III breast cancer: Clinical response and long-tern survival.
  Swain, S.M., Jahanzeb, M. Erban, J.K., Limentani, S.A., Hardikar, S., Tsai, D.T., Olsen, S.R., Gradishar, W.J., National Cancer Institute, Bethesda, MD; Comprehensive ..., American Society of Clinical Oncology, 1/1/2003
• Join now to see all

Lectures

• 9th Annual New Orleans Summer Cancer Meeting 
  New Orleans, LA - 1/1/2014
• “Lung Cancer” 
  Deland, FL - 1/1/2014
• “Targeted Therapy for Lung Cancer: A Case Based Presentation” 
  Jacksonville, FL - 1/1/2014
• “Evaluation of Genomic Platforms in Invasive Breast Cancer: A Review of Clinical Validation Evidence and Two Head-to-Head Clinical Utility Studies”. 
  1/23/2013
• “Management of Bone Metastasis in Breast Cancer”. 
  Goiania, Brazil - 1/23/2013
• “Blockades and Barricades in the HER Family of Receptors” 
  Miami, FL - 1/1/2013
• “NCCN Overview: Guidelines Development and Implementation in the United States”. 
  Namibia, South Africa - 1/26/2012
• “NCCN International Initiatives" 
  Namibia, South Africa - 1/26/2012
• “Challenges in Adaptation and Adoption of the NCCN Guidelines” 
  Moscow, Russia - 1/19/2012
• “NCCN” Guidelines Process: International Adaptations”. 
  Salvador, Brazil - 1/10/2012
• “Neoadjuvant Chemotherapy in Breast Cancer”. 
  Salvador, Brazil - 1/10/2012
• "NCCN Guidelines: The Process of Guideline Development”. 
  Lahore, Pakistan - 1/8/2012
• “Towards More Personalized Therapy for Non-Small Lung Carcinoma" 
  Lahore, Pakistan - 1/8/2012
• “Estimating Risk of Recurrence in Early Stage Breast Cancer”. 
  Lahore, Pakistan - 1/8/2012
• “Challenges and Opportunities in the International Adaptation of the NCCN Guidelines” 
  Doha, Qatar - 1/1/2012
• San Antonio Breast Cancer Conference Symposium 
  San Antonio, TX - 1/1/2012
• “Consideration in Curative Systemic Therapy of Early Breast Cancer”. 
  Memphis, TN - 1/1/2012
• “Evolution of HER2 Directed Therapy in Breast Cancer”. 
  Memphis, TN - 1/1/2012
• “Options in the Treatment of Metastatic Breast Cancer” 
  Phoenix, AZ - 1/1/2012
• “Updates in the Treatment of Metastatic Breast Cancer” 
  Jamaica, NY - 1/1/2012
• “Breast Cancer Academic Advisory Board” 
  San Francisco, CA - 1/1/2012
• “FLASCO Fall Meeting” 
  Tampa, FL - 1/1/2011
• “Expert Forum on HER2+ Breast Cancer” 
  Miami, FL - 1/1/2011
• “Systemic Treatment of HER2+ Breast Cancer” 
  Port St. Lucie, FL - 1/1/2011
• “Economic Implications of Cancer and Cancer Treatment” “Impact of Guidelines in Clinical Practice” 
  Gramado, Brazil - 1/1/2011
• Join now to see all

Other

• “Focus on Cytotoxic Therapy” 
  Jahanzeb M, Yardley D, Recent Progress in Metastatic Breast Cancer, Physicians’ Education Resource
  1/1/2013
• “Avastin Breast / Herceptin Breast” (National Audio/Web Conference) 
  Jahanzeb M
  1/1/2009
• “Current Debates in the Treatment of HER 2+ Metastatic Breast Cancer” (National Audio/Web Conference) 
  Jahanzeb M
  1/1/2008
• "New Developments in the Management of Advanced Breast Cancer” (National Audio/Web Conference) 
  Jahanzeb M
  1/1/2007
• “Clinical Review: Trastuzumab: the foundation of care for HER2-positive breast cancer.” (it is an insert within the regular issue and is numbered separately). 
  Jahanzeb M, Oncology Nursing News
  1/1/2007
• “Trastuzumab: The Foundation of Care for HER2-positive Breast Cancer” (it is an insert within the regular issue and is numbered separately). 
  Jahanzeb M, Oncology Nursing News
  1/1/2007
• “Advances in the Treatment of Breast Cancer” 
  Sachdev J, Jahanzeb M, The Memphis Medical Society Quarterly
  1/1/2007
• “A Patient with Bilateral Breast Cancer Treated with Neoadjuvant and Adjuvant Trastuzumab” 
  Sachdev J, Jahanzeb M, Case Studies in Breast Cancer
  1/1/2007
• “Help Your Health Care Team Help You” 
  Jahanzeb M, Caring4Cancer
  1/1/2007
• “Sexuality and Cancer” 
  Jahanzeb M, Caring4Cancer
  1/1/2007
• "The New Targeted Therapies: What You Should Know” 
  Jahanzeb M, Caring4Cancer
  1/1/2007
• “Managing Side Effects of Cancer Treatments” 
  Jahanzeb M, Caring4Cancer
  1/1/2007
• “Controversies Surrounding the Optimal Use of Chemotherapy in Breast Cancer” (National Audio/Web Conference) 
  Jahanzeb M
  1/1/2006
• “Management of a Patient with HER2-Overexpressing Infiltrating Ductal Carcinoma with Ductal Carcinoma In Situ” 
  Jahanzeb M, Leyland-Jones B, Oncology Consultations
  1/1/2006
• “How to Choose Therapy" 
  Jahanzeb M, Galleshaw J, Caring4Cancer
  1/1/2006
• "Adjuvant Chemotherapeutic Treatment of Node-Positive, Hormone-Negative Breast Cancer” 
  Jahanzeb M, Vogel C, Oncology Consultations
  1/1/2006
• “After Diagnosis of Non-Small Cell Lung Cancer, The Real Workup Begins” 
  Rosenthal, M, Jahanzeb, M, Hem/Onc Today
  1/1/2005
• “An Overview of Anti-HER2 Therapy in Combination with Chemotherapy in Metastatic Breast Cancer” 
  Jahanzeb M, Biological Therapy of Breast Cancer
  1/1/2004
• “A Patient With HER2 Positive Metastatic Breast Carcinoma Treated with Trastuzumab Based Therapy” 
  Aslam R, Jahanzeb M, Physicians’ Education Resource
  1/1/2004
• “Treatment of HER2-Overexpressing Metastatic Breast Cancer with Chemotherapy and Anti-HER2 Monoclonal Antibody” 
  Jahanzeb M, Human Epidermal Growth Factor Receptors in Oncology
  1/1/2004
• “Off-label use of Herceptin within Managed Care Settings and Hospitals” (National Audio/Web Conference) 
  Jahanzeb M
  1/1/2002
• “Targeted Therapies for Advanced Breast Cancer” (National Audio/Web Conference) 
  Jahanzeb M
  1/1/2002
• “HER2 Testing in Breast Cancer: What is the Best Strategy” (National Audio/Web Conference) 
  Jahanzeb M
  1/1/2002
• “Update in Chemotherapy of Metastatic Breast Cancer” (National Audio/Web Conference) 
  Jahanzeb M
  1/1/2002
• “Advances in the Management of Metastatic Breast Cancer” (National Audio/Web Conference) 
  Jahanzeb M
  1/1/2001
• Join now to see all